Down Syndrome Market is segemented By Type of Disease (Translocation Down Syndrome, Mosaic Down Syndrome, Trisomy 21), By End-use (Hospitals and Clinics, Home Healthcare ....
Market Size in USD
CAGR5.1%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 5.1% |
Market Concentration | High |
Major Players | AC Immune SA, Alzheon, Inc., Annovis Bio, Inc., ManRos Therapeutics, NeuroNascent, Inc. |
The Global Down Syndrome Market is estimated to be valued at USD 1.8 Bn in 2024 and is expected to reach USD 5.2 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5.1% from 2024 to 2031. The market serves the needs of people with Down Syndrome through innovative treatment options, therapies, and supportive care services.
The market is expected to witness positive growth over the forecast period owing to rising prevalence of Down Syndrome, increasing government initiatives to support people with intellectual disabilities, and continuous development of novel drugs and therapies to improve quality of life. However, lack of disease-modifying drugs and high cost of advanced therapies are some challenges hindering faster adoption.